paroxetine	Carbamazepine	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
paroxetine	Fluoxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	none	none	none
paroxetine	Fluoxetine	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	none	none	none
paroxetine	Fluoxetine	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	none	none	none
paroxetine	Fluoxetine	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	none	none	none
paroxetine	Fluoxetine	19	21	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
paroxetine	Fluoxetine	19	20	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
paroxetine	Fluoxetine	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
paroxetine	Fluoxetine	21	20	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
paroxetine	Fluoxetine	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
paroxetine	Fluoxetine	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
paroxetine	Fluoxetine	20	20	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
paroxetine	Risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
paroxetine	Risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
paroxetine	Risperidone	17	16	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
paroxetine	Risperidone	17	16	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
paroxetine	Risperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	Risperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	Risperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
paroxetine	Risperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
paroxetine	Risperidone	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	Risperidone	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	Risperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	Risperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	Risperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	Risperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	Risperidone	19	21	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	Risperidone	19	21	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	Risperidone	19	20	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	Risperidone	19	20	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	Risperidone	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	Risperidone	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	Risperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	Risperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	Risperidone	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	Risperidone	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	Risperidone	21	23	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
paroxetine	Risperidone	21	23	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
paroxetine	Risperidone	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
paroxetine	Risperidone	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
paroxetine	Risperidone	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	Risperidone	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	Risperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	Risperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	Risperidone	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	Risperidone	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	Risperidone	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	Risperidone	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	Risperidone	20	22	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
paroxetine	Risperidone	20	22	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
paroxetine	fluoxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	none	none	none
paroxetine	fluoxetine	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	none	none	none
paroxetine	fluoxetine	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	none	none	none
paroxetine	fluoxetine	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	none	none	none
paroxetine	fluoxetine	19	21	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
paroxetine	fluoxetine	19	20	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
paroxetine	fluoxetine	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
paroxetine	fluoxetine	21	20	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
paroxetine	fluoxetine	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
paroxetine	fluoxetine	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
paroxetine	fluoxetine	20	20	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
paroxetine	risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
paroxetine	risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
paroxetine	risperidone	17	16	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
paroxetine	risperidone	17	16	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
paroxetine	risperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	risperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	risperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
paroxetine	risperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
paroxetine	risperidone	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	risperidone	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	risperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	risperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	risperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	risperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
paroxetine	risperidone	19	21	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	risperidone	19	21	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	risperidone	19	20	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	risperidone	19	20	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	risperidone	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	risperidone	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	risperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	risperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	risperidone	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	risperidone	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	risperidone	21	23	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
paroxetine	risperidone	21	23	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
paroxetine	risperidone	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
paroxetine	risperidone	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
paroxetine	risperidone	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	risperidone	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	risperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	risperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	risperidone	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	risperidone	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
paroxetine	risperidone	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	risperidone	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
paroxetine	risperidone	20	22	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
paroxetine	risperidone	20	22	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
paroxetine	carbamazepine	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
paroxetine	Erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
paroxetine	Erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
paroxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	19	21	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	19	21	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
paroxetine	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
paroxetine	erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
paroxetine	erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
dopamine	cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	2541	none	2541
dopamine	cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	2541	none	2541
dopamine	Amitriptyline	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		none	704	none	704
dopamine	Amitriptyline	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		none	704	none	704
dopamine	alcohol	3	1	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	none	none	none
dopamine	Risperidone	3	1	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	Risperidone	3	1	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	Risperidone	3	2	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	Risperidone	3	2	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	Risperidone	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	Risperidone	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	Risperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		none	35636	none	35636
dopamine	Risperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		none	35636	none	35636
dopamine	Risperidone	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	35636	none	35636
dopamine	Risperidone	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	35636	none	35636
dopamine	Ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	9143	none	D011899
dopamine	Ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	9143	none	D011899
dopamine	risperidone	3	1	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	risperidone	3	1	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	risperidone	3	2	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	risperidone	3	2	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	risperidone	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	risperidone	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
dopamine	risperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		none	35636	none	35636
dopamine	risperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		none	35636	none	35636
dopamine	risperidone	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	35636	none	35636
dopamine	risperidone	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	35636	none	35636
dopamine	ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	9143	none	D011899
dopamine	ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	9143	none	D011899
dopamine	9-hydroxyrisperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		none	679314	none	C079150
dopamine	9-hydroxyrisperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		none	679314	none	C079150
dopamine	Levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	6375	none	D007980
dopamine	Levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	6375	none	D007980
dopamine	levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	6375	none	D007980
dopamine	levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	6375	none	D007980
dopamine	Cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	2541	none	2541
dopamine	Cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		none	2541	none	2541
phenobarbital	Carbamazepine	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
phenobarbital	Carbamazepine	26	24	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
phenobarbital	Risperidone	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenobarbital	Risperidone	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenobarbital	Risperidone	26	27	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		none	35636	none	35636
phenobarbital	Risperidone	26	27	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		none	35636	none	35636
phenobarbital	Risperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenobarbital	Risperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenobarbital	Risperidone	26	28	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		none	35636	none	35636
phenobarbital	Risperidone	26	28	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		none	35636	none	35636
phenobarbital	phenytoin	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
phenobarbital	risperidone	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenobarbital	risperidone	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenobarbital	risperidone	26	27	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		none	35636	none	35636
phenobarbital	risperidone	26	27	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		none	35636	none	35636
phenobarbital	risperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenobarbital	risperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenobarbital	risperidone	26	28	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		none	35636	none	35636
phenobarbital	risperidone	26	28	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		none	35636	none	35636
phenobarbital	carbamazepine	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
phenobarbital	carbamazepine	26	24	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
phenobarbital	rifampin	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
phenobarbital	9-hydroxyrisperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
phenobarbital	9-hydroxyrisperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
Digoxin	Risperidone	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	Risperidone	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	Risperidone	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	Risperidone	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	Risperidone	11	11	true	negative	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	Risperidone	11	11	true	negative	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	Risperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		3407	35636	3407	35636
Digoxin	Risperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		3407	35636	3407	35636
Digoxin	Risperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		3407	35636	3407	35636
Digoxin	Risperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		3407	35636	3407	35636
Digoxin	Valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
Digoxin	Valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
Digoxin	Valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
Digoxin	Valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
Digoxin	risperidone	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	risperidone	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	risperidone	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	risperidone	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	risperidone	11	11	true	negative	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	risperidone	11	11	true	negative	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
Digoxin	risperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		3407	35636	3407	35636
Digoxin	risperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		3407	35636	3407	35636
Digoxin	risperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		3407	35636	3407	35636
Digoxin	risperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		3407	35636	3407	35636
Digoxin	valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
Digoxin	valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
Digoxin	valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
Digoxin	valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
Digoxin	9-hydroxyrisperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		3407	679314	3407	C079150
Digoxin	9-hydroxyrisperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		3407	679314	3407	C079150
Digoxin	9-hydroxyrisperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		3407	679314	3407	C079150
Digoxin	9-hydroxyrisperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		3407	679314	3407	C079150
cimetidine	Amitriptyline	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	704	2541	704
cimetidine	Amitriptyline	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	704	2541	704
cimetidine	Amitriptyline	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	704	2541	704
cimetidine	Amitriptyline	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	704	2541	704
cimetidine	Risperidone	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	Risperidone	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	Risperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	Risperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	Risperidone	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	Risperidone	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	Risperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	Risperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	Risperidone	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	35636	2541	35636
cimetidine	Risperidone	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	35636	2541	35636
cimetidine	Risperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	Risperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	Risperidone	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	Risperidone	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	Risperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	Risperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	Risperidone	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	35636	2541	35636
cimetidine	Risperidone	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	35636	2541	35636
cimetidine	Risperidone	6	8	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		2541	35636	2541	35636
cimetidine	Risperidone	6	8	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		2541	35636	2541	35636
cimetidine	Ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	9143	2541	D011899
cimetidine	Ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	9143	2541	D011899
cimetidine	Ranitidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	Ranitidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	Ranitidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	Ranitidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	Ranitidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	Ranitidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	risperidone	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	risperidone	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	risperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	risperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	risperidone	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	risperidone	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	35636	2541	35636
cimetidine	risperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	risperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	risperidone	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	35636	2541	35636
cimetidine	risperidone	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	35636	2541	35636
cimetidine	risperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	risperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	risperidone	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	risperidone	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	risperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	risperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	35636	2541	35636
cimetidine	risperidone	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	35636	2541	35636
cimetidine	risperidone	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	35636	2541	35636
cimetidine	risperidone	6	8	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		2541	35636	2541	35636
cimetidine	risperidone	6	8	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		2541	35636	2541	35636
cimetidine	Clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	2626	2541	D003024
cimetidine	Clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	2626	2541	D003024
cimetidine	Clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	2626	2541	D003024
cimetidine	Clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	2626	2541	D003024
cimetidine	ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	9143	2541	D011899
cimetidine	ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	9143	2541	D011899
cimetidine	ranitidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	ranitidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	ranitidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	ranitidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	ranitidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	ranitidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	9143	2541	D011899
cimetidine	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	679314	2541	C079150
cimetidine	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	679314	2541	C079150
cimetidine	9-hydroxyrisperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	679314	2541	C079150
cimetidine	9-hydroxyrisperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	679314	2541	C079150
cimetidine	9-hydroxyrisperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	679314	2541	C079150
cimetidine	9-hydroxyrisperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	679314	2541	C079150
cimetidine	9-hydroxyrisperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	679314	2541	C079150
cimetidine	9-hydroxyrisperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		2541	679314	2541	C079150
cimetidine	Levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	6375	2541	D007980
cimetidine	Levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	6375	2541	D007980
cimetidine	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	2626	2541	D003024
cimetidine	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	2626	2541	D003024
cimetidine	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	2626	2541	D003024
cimetidine	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2541	2626	2541	D003024
cimetidine	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	6375	2541	D007980
cimetidine	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		2541	6375	2541	D007980
Amitriptyline	Risperidone	4	2	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	Risperidone	4	2	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	Risperidone	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	Risperidone	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	Risperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	Risperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	Risperidone	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		704	35636	704	35636
Amitriptyline	Risperidone	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		704	35636	704	35636
Amitriptyline	Risperidone	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	35636	704	35636
Amitriptyline	Risperidone	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	35636	704	35636
Amitriptyline	Ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		704	9143	704	D011899
Amitriptyline	Ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		704	9143	704	D011899
Amitriptyline	Ranitidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	9143	704	D011899
Amitriptyline	Ranitidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	9143	704	D011899
Amitriptyline	risperidone	4	2	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	risperidone	4	2	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	risperidone	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	risperidone	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	risperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	risperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	35636	704	35636
Amitriptyline	risperidone	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		704	35636	704	35636
Amitriptyline	risperidone	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		704	35636	704	35636
Amitriptyline	risperidone	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	35636	704	35636
Amitriptyline	risperidone	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	35636	704	35636
Amitriptyline	ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		704	9143	704	D011899
Amitriptyline	ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		704	9143	704	D011899
Amitriptyline	ranitidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	9143	704	D011899
Amitriptyline	ranitidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	9143	704	D011899
Amitriptyline	9-hydroxyrisperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	679314	704	C079150
Amitriptyline	9-hydroxyrisperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	679314	704	C079150
Amitriptyline	9-hydroxyrisperidone	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	679314	704	C079150
Amitriptyline	9-hydroxyrisperidone	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	679314	704	C079150
Amitriptyline	Levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	6375	704	D007980
Amitriptyline	Levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	6375	704	D007980
Amitriptyline	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	6375	704	D007980
Amitriptyline	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		704	6375	704	D007980
Amitriptyline	Cimetidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		704	2541	704	2541
Amitriptyline	Cimetidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		704	2541	704	2541
Amitriptyline	Cimetidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	2541	704	2541
Amitriptyline	Cimetidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		704	2541	704	2541
Carbamazepine	Fluoxetine	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
Carbamazepine	Risperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	Risperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	Risperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	Risperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	Risperidone	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	Risperidone	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	Risperidone	23	25	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	Risperidone	23	25	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	Risperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	Risperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	Risperidone	25	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	Risperidone	25	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	Risperidone	25	27	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		none	35636	none	35636
Carbamazepine	Risperidone	25	27	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		none	35636	none	35636
Carbamazepine	Risperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
Carbamazepine	Risperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
Carbamazepine	Risperidone	24	23	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	35636	none	35636
Carbamazepine	Risperidone	24	23	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	35636	none	35636
Carbamazepine	Risperidone	24	22	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	35636	none	35636
Carbamazepine	Risperidone	24	22	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	35636	none	35636
Carbamazepine	Risperidone	24	25	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	Risperidone	24	25	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	Risperidone	24	26	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
Carbamazepine	Risperidone	24	26	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
Carbamazepine	phenytoin	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
Carbamazepine	phenytoin	24	26	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
Carbamazepine	fluoxetine	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
Carbamazepine	risperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	risperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	risperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	risperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	risperidone	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	risperidone	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Carbamazepine	risperidone	23	25	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	risperidone	23	25	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	risperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	risperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	risperidone	25	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	risperidone	25	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	risperidone	25	27	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		none	35636	none	35636
Carbamazepine	risperidone	25	27	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		none	35636	none	35636
Carbamazepine	risperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
Carbamazepine	risperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
Carbamazepine	risperidone	24	23	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	35636	none	35636
Carbamazepine	risperidone	24	23	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	35636	none	35636
Carbamazepine	risperidone	24	22	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	35636	none	35636
Carbamazepine	risperidone	24	22	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	35636	none	35636
Carbamazepine	risperidone	24	25	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	risperidone	24	25	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	35636	none	35636
Carbamazepine	risperidone	24	26	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
Carbamazepine	risperidone	24	26	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
Carbamazepine	rifampin	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
Carbamazepine	rifampin	24	26	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
Carbamazepine	Erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
Carbamazepine	Erythromycin	24	22	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	none	none	none
Carbamazepine	Paroxetine	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
Carbamazepine	9-hydroxyrisperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
Carbamazepine	9-hydroxyrisperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
Carbamazepine	9-hydroxyrisperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
Carbamazepine	9-hydroxyrisperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
Carbamazepine	9-hydroxyrisperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	679314	none	C079150
Carbamazepine	9-hydroxyrisperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	679314	none	C079150
Carbamazepine	9-hydroxyrisperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
Carbamazepine	9-hydroxyrisperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
Carbamazepine	9-hydroxyrisperidone	24	23	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	679314	none	C079150
Carbamazepine	9-hydroxyrisperidone	24	23	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	679314	none	C079150
Carbamazepine	9-hydroxyrisperidone	24	26	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
Carbamazepine	9-hydroxyrisperidone	24	26	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
Carbamazepine	erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
Carbamazepine	erythromycin	24	22	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	none	none	none
alcohol	Risperidone	1	1	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  		none	35636	none	35636
alcohol	Risperidone	1	1	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  		none	35636	none	35636
alcohol	Risperidone	1	2	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  		none	35636	none	35636
alcohol	Risperidone	1	2	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  		none	35636	none	35636
alcohol	Risperidone	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
alcohol	Risperidone	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
alcohol	risperidone	1	1	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  		none	35636	none	35636
alcohol	risperidone	1	1	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  		none	35636	none	35636
alcohol	risperidone	1	2	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  		none	35636	none	35636
alcohol	risperidone	1	2	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  		none	35636	none	35636
alcohol	risperidone	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
alcohol	risperidone	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	35636	none	35636
alcohol	Levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	6375	none	D007980
alcohol	Levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	6375	none	D007980
alcohol	levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	6375	none	D007980
alcohol	levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		none	6375	none	D007980
Fluoxetine	Risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
Fluoxetine	Risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
Fluoxetine	Risperidone	17	16	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
Fluoxetine	Risperidone	17	16	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
Fluoxetine	Risperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
Fluoxetine	Risperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
Fluoxetine	Risperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	18	16	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	18	16	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
Fluoxetine	Risperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
Fluoxetine	Risperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	Risperidone	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	Risperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	Risperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	Risperidone	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	Risperidone	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	Risperidone	21	23	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Fluoxetine	Risperidone	21	23	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Fluoxetine	Risperidone	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
Fluoxetine	Risperidone	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
Fluoxetine	Risperidone	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	Risperidone	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	Risperidone	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	Risperidone	20	22	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
Fluoxetine	Risperidone	20	22	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
Fluoxetine	risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
Fluoxetine	risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
Fluoxetine	risperidone	17	16	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
Fluoxetine	risperidone	17	16	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
Fluoxetine	risperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
Fluoxetine	risperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
Fluoxetine	risperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	risperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	risperidone	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	risperidone	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	risperidone	18	16	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	risperidone	18	16	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	risperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
Fluoxetine	risperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
Fluoxetine	risperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	risperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
Fluoxetine	risperidone	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	risperidone	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	risperidone	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	risperidone	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	risperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	risperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	risperidone	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	risperidone	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	risperidone	21	23	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Fluoxetine	risperidone	21	23	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
Fluoxetine	risperidone	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
Fluoxetine	risperidone	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
Fluoxetine	risperidone	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	risperidone	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	risperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	risperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	risperidone	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	risperidone	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
Fluoxetine	risperidone	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	risperidone	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
Fluoxetine	risperidone	20	22	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
Fluoxetine	risperidone	20	22	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
Fluoxetine	carbamazepine	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
Fluoxetine	Erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
Fluoxetine	Erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
Fluoxetine	Paroxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	none	none	none
Fluoxetine	Paroxetine	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	none	none	none
Fluoxetine	Paroxetine	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	none	none	none
Fluoxetine	Paroxetine	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	none	none	none
Fluoxetine	Paroxetine	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
Fluoxetine	Paroxetine	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
Fluoxetine	Paroxetine	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
Fluoxetine	Paroxetine	21	20	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
Fluoxetine	Paroxetine	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
Fluoxetine	Paroxetine	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
Fluoxetine	Paroxetine	20	20	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
Fluoxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Fluoxetine	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Fluoxetine	erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
Fluoxetine	erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
Risperidone	Valproate	7	9	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	Valproate	7	9	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	Valproate	8	9	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	Valproate	8	9	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	Valproate	8	10	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	Valproate	8	10	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	Valproate	9	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	Valproate	9	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	Valproate	9	10	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	Valproate	9	10	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	Valproate	10	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	Valproate	10	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	Valproate	10	10	true	positive	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	Valproate	10	10	true	positive	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	Valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
Risperidone	Valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
Risperidone	Valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
Risperidone	Valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
Risperidone	Valproate	12	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	40254	35636	40254
Risperidone	Valproate	12	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	40254	35636	40254
Risperidone	digoxin	9	11	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	3407	35636	3407
Risperidone	digoxin	9	11	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	3407	35636	3407
Risperidone	digoxin	10	11	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	3407	35636	3407
Risperidone	digoxin	10	11	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	3407	35636	3407
Risperidone	digoxin	11	11	true	negative	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	3407	35636	3407
Risperidone	digoxin	11	11	true	negative	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	3407	35636	3407
Risperidone	digoxin	12	11	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	3407	35636	3407
Risperidone	digoxin	12	11	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	3407	35636	3407
Risperidone	digoxin	13	11	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	3407	35636	3407
Risperidone	digoxin	13	11	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	3407	35636	3407
Risperidone	phenytoin	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	phenytoin	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	phenytoin	27	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	none	35636	none
Risperidone	phenytoin	27	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	none	35636	none
Risperidone	phenytoin	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	phenytoin	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	phenytoin	28	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		35636	none	35636	none
Risperidone	phenytoin	28	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		35636	none	35636	none
Risperidone	Ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	Ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	Ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	Ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	Ranitidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	Ranitidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	Ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	Ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	Ranitidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	Ranitidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	Ranitidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	Ranitidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	Ranitidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	Ranitidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	Ranitidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
Risperidone	Ranitidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
Risperidone	Ranitidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
Risperidone	Ranitidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
Risperidone	Ranitidine	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	9143	35636	D011899
Risperidone	Ranitidine	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	9143	35636	D011899
Risperidone	fluoxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
Risperidone	fluoxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
Risperidone	fluoxetine	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
Risperidone	fluoxetine	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
Risperidone	fluoxetine	16	17	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
Risperidone	fluoxetine	16	17	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
Risperidone	fluoxetine	16	18	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
Risperidone	fluoxetine	16	18	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
Risperidone	fluoxetine	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	fluoxetine	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	fluoxetine	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	fluoxetine	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	fluoxetine	19	21	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	fluoxetine	19	21	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	fluoxetine	19	20	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	fluoxetine	19	20	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	fluoxetine	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
Risperidone	fluoxetine	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
Risperidone	fluoxetine	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
Risperidone	fluoxetine	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
Risperidone	fluoxetine	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	fluoxetine	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	fluoxetine	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	fluoxetine	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	fluoxetine	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	fluoxetine	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	fluoxetine	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	fluoxetine	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	fluoxetine	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	fluoxetine	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	fluoxetine	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	fluoxetine	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	fluoxetine	23	21	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	fluoxetine	23	21	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	fluoxetine	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	fluoxetine	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	fluoxetine	22	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	fluoxetine	22	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	galantamine	27	29	false	none	7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	galantamine	27	29	false	none	7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	galantamine	29	29	false	none	In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	galantamine	29	29	false	none	In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	galantamine	28	29	false	none	Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	galantamine	28	29	false	none	Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	carbamazepine	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	carbamazepine	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	carbamazepine	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	carbamazepine	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	carbamazepine	23	25	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
Risperidone	carbamazepine	23	25	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
Risperidone	carbamazepine	23	24	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		35636	none	35636	none
Risperidone	carbamazepine	23	24	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		35636	none	35636	none
Risperidone	carbamazepine	22	23	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	carbamazepine	22	23	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	carbamazepine	22	24	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		35636	none	35636	none
Risperidone	carbamazepine	22	24	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		35636	none	35636	none
Risperidone	carbamazepine	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
Risperidone	carbamazepine	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
Risperidone	carbamazepine	25	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
Risperidone	carbamazepine	25	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
Risperidone	carbamazepine	25	24	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
Risperidone	carbamazepine	25	24	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
Risperidone	carbamazepine	27	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	none	35636	none
Risperidone	carbamazepine	27	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	none	35636	none
Risperidone	carbamazepine	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	carbamazepine	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	carbamazepine	26	24	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	carbamazepine	26	24	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	Clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	Clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	Clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	Clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	Clozapine	7	7	false	none	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	Clozapine	7	7	false	none	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	Clozapine	8	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2626	35636	D003024
Risperidone	Clozapine	8	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2626	35636	D003024
Risperidone	Clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	2626	35636	D003024
Risperidone	Clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	2626	35636	D003024
Risperidone	rifampin	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	rifampin	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	rifampin	27	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	none	35636	none
Risperidone	rifampin	27	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	none	35636	none
Risperidone	rifampin	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	rifampin	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
Risperidone	rifampin	28	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		35636	none	35636	none
Risperidone	rifampin	28	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		35636	none	35636	none
Risperidone	Erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	Erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	Erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	Erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	Erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	Erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	Erythromycin	22	22	false	none	Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	Erythromycin	22	22	false	none	Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	valproate	7	9	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	valproate	7	9	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	valproate	8	9	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	valproate	8	9	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	valproate	8	10	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	valproate	8	10	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	valproate	9	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	valproate	9	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
Risperidone	valproate	9	10	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	valproate	9	10	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	valproate	10	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	valproate	10	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	valproate	10	10	true	positive	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	valproate	10	10	true	positive	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
Risperidone	valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
Risperidone	valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
Risperidone	valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
Risperidone	valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
Risperidone	valproate	12	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	40254	35636	40254
Risperidone	valproate	12	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	40254	35636	40254
Risperidone	Paroxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
Risperidone	Paroxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
Risperidone	Paroxetine	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	Paroxetine	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	Paroxetine	16	17	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
Risperidone	Paroxetine	16	17	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
Risperidone	Paroxetine	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	Paroxetine	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	Paroxetine	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	Paroxetine	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	Paroxetine	19	21	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	Paroxetine	19	21	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	Paroxetine	19	20	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	Paroxetine	19	20	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	Paroxetine	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
Risperidone	Paroxetine	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
Risperidone	Paroxetine	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	Paroxetine	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
Risperidone	Paroxetine	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	Paroxetine	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	Paroxetine	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	Paroxetine	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	Paroxetine	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	Paroxetine	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	Paroxetine	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	Paroxetine	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	Paroxetine	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	Paroxetine	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	Paroxetine	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	Paroxetine	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
Risperidone	Paroxetine	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	Paroxetine	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
Risperidone	Paroxetine	23	21	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	Paroxetine	23	21	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	Paroxetine	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	Paroxetine	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	Paroxetine	22	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	Paroxetine	22	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	ranitidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	ranitidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
Risperidone	ranitidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	ranitidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	ranitidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	ranitidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	ranitidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	ranitidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
Risperidone	ranitidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
Risperidone	ranitidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
Risperidone	ranitidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
Risperidone	ranitidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
Risperidone	ranitidine	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	9143	35636	D011899
Risperidone	ranitidine	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	9143	35636	D011899
Risperidone	donepezil	27	29	false	none	7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	donepezil	27	29	false	none	7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	donepezil	29	29	false	none	In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	donepezil	29	29	false	none	In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	donepezil	28	29	false	none	Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	donepezil	28	29	false	none	Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
Risperidone	9-hydroxyrisperidone	2	4	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	2	4	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	12	12	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	12	12	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	12	13	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	12	13	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	13	12	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	13	12	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	13	13	false	none	Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	13	13	false	none	Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	16	18	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	16	18	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	19	21	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	19	21	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	22	23	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	22	23	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	27	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	27	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	28	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		35636	679314	35636	C079150
Risperidone	9-hydroxyrisperidone	28	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		35636	679314	35636	C079150
Risperidone	Levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	Levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	Levodopa	2	3	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	Levodopa	2	3	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	Levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	Levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	Levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	6375	35636	D007980
Risperidone	Levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	6375	35636	D007980
Risperidone	Levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	6375	35636	D007980
Risperidone	Levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	6375	35636	D007980
Risperidone	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	clozapine	7	7	false	none	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	clozapine	7	7	false	none	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
Risperidone	clozapine	8	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2626	35636	D003024
Risperidone	clozapine	8	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2626	35636	D003024
Risperidone	clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	2626	35636	D003024
Risperidone	clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	2626	35636	D003024
Risperidone	levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	levodopa	2	3	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	levodopa	2	3	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
Risperidone	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	6375	35636	D007980
Risperidone	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	6375	35636	D007980
Risperidone	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	6375	35636	D007980
Risperidone	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	6375	35636	D007980
Risperidone	erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
Risperidone	erythromycin	22	22	false	none	Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	erythromycin	22	22	false	none	Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
Risperidone	Cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
Risperidone	Cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
Risperidone	Cimetidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
Risperidone	Cimetidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
Risperidone	Cimetidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
Risperidone	Cimetidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
Risperidone	Cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
Risperidone	Cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
Risperidone	Cimetidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
Risperidone	Cimetidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
Risperidone	Cimetidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
Risperidone	Cimetidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
Risperidone	Cimetidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
Risperidone	Cimetidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
Risperidone	Cimetidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2541	35636	2541
Risperidone	Cimetidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2541	35636	2541
Risperidone	Cimetidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2541	35636	2541
Risperidone	Cimetidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2541	35636	2541
Risperidone	Cimetidine	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2541	35636	2541
Risperidone	Cimetidine	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2541	35636	2541
Valproate	digoxin	9	11	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		40254	3407	40254	3407
Valproate	digoxin	9	11	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		40254	3407	40254	3407
Valproate	digoxin	10	11	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		40254	3407	40254	3407
Valproate	digoxin	10	11	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		40254	3407	40254	3407
Valproate	risperidone	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	35636	40254	35636
Valproate	risperidone	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	35636	40254	35636
Valproate	risperidone	9	8	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	35636	40254	35636
Valproate	risperidone	9	8	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	35636	40254	35636
Valproate	risperidone	9	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	35636	40254	35636
Valproate	risperidone	9	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	35636	40254	35636
Valproate	risperidone	9	10	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		40254	35636	40254	35636
Valproate	risperidone	9	10	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		40254	35636	40254	35636
Valproate	risperidone	9	11	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		40254	35636	40254	35636
Valproate	risperidone	9	11	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		40254	35636	40254	35636
Valproate	risperidone	10	8	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		40254	35636	40254	35636
Valproate	risperidone	10	8	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		40254	35636	40254	35636
Valproate	risperidone	10	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		40254	35636	40254	35636
Valproate	risperidone	10	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		40254	35636	40254	35636
Valproate	risperidone	10	10	true	positive	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		40254	35636	40254	35636
Valproate	risperidone	10	10	true	positive	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		40254	35636	40254	35636
Valproate	risperidone	10	11	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		40254	35636	40254	35636
Valproate	risperidone	10	11	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		40254	35636	40254	35636
Valproate	risperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		40254	35636	40254	35636
Valproate	risperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		40254	35636	40254	35636
Valproate	Clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	2626	40254	D003024
Valproate	Clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	2626	40254	D003024
Valproate	9-hydroxyrisperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		40254	679314	40254	C079150
Valproate	9-hydroxyrisperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		40254	679314	40254	C079150
Valproate	clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	2626	40254	D003024
Valproate	clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	2626	40254	D003024
digoxin	risperidone	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
digoxin	risperidone	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
digoxin	risperidone	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
digoxin	risperidone	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
digoxin	risperidone	11	11	true	negative	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
digoxin	risperidone	11	11	true	negative	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	35636	3407	35636
digoxin	risperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		3407	35636	3407	35636
digoxin	risperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		3407	35636	3407	35636
digoxin	risperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		3407	35636	3407	35636
digoxin	risperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		3407	35636	3407	35636
digoxin	valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
digoxin	valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
digoxin	valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
digoxin	valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		3407	40254	3407	40254
digoxin	9-hydroxyrisperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		3407	679314	3407	C079150
digoxin	9-hydroxyrisperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		3407	679314	3407	C079150
digoxin	9-hydroxyrisperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		3407	679314	3407	C079150
digoxin	9-hydroxyrisperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		3407	679314	3407	C079150
phenytoin	risperidone	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenytoin	risperidone	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenytoin	risperidone	26	27	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		none	35636	none	35636
phenytoin	risperidone	26	27	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		none	35636	none	35636
phenytoin	risperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenytoin	risperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	35636	none	35636
phenytoin	risperidone	26	28	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		none	35636	none	35636
phenytoin	risperidone	26	28	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		none	35636	none	35636
phenytoin	carbamazepine	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
phenytoin	carbamazepine	26	24	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
phenytoin	rifampin	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
phenytoin	9-hydroxyrisperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
phenytoin	9-hydroxyrisperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
Ranitidine	risperidone	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	35636	D011899	35636
Ranitidine	risperidone	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	35636	D011899	35636
Ranitidine	risperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	35636	D011899	35636
Ranitidine	risperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	35636	D011899	35636
Ranitidine	risperidone	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	35636	D011899	35636
Ranitidine	risperidone	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	35636	D011899	35636
Ranitidine	risperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	35636	D011899	35636
Ranitidine	risperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	35636	D011899	35636
Ranitidine	risperidone	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	35636	D011899	35636
Ranitidine	risperidone	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	35636	D011899	35636
Ranitidine	risperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	35636	D011899	35636
Ranitidine	risperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	35636	D011899	35636
Ranitidine	risperidone	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	35636	D011899	35636
Ranitidine	risperidone	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	35636	D011899	35636
Ranitidine	risperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	35636	D011899	35636
Ranitidine	risperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	35636	D011899	35636
Ranitidine	risperidone	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	35636	D011899	35636
Ranitidine	risperidone	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	35636	D011899	35636
Ranitidine	risperidone	6	8	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		9143	35636	D011899	35636
Ranitidine	risperidone	6	8	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		9143	35636	D011899	35636
Ranitidine	Clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
Ranitidine	Clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
Ranitidine	Clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
Ranitidine	Clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
Ranitidine	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	679314	D011899	C079150
Ranitidine	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	679314	D011899	C079150
Ranitidine	9-hydroxyrisperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
Ranitidine	9-hydroxyrisperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
Ranitidine	9-hydroxyrisperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
Ranitidine	9-hydroxyrisperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
Ranitidine	9-hydroxyrisperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
Ranitidine	9-hydroxyrisperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
Ranitidine	Levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	6375	D011899	D007980
Ranitidine	Levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	6375	D011899	D007980
Ranitidine	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
Ranitidine	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
Ranitidine	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
Ranitidine	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
Ranitidine	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	6375	D011899	D007980
Ranitidine	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	6375	D011899	D007980
Ranitidine	Cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	2541	D011899	2541
Ranitidine	Cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	2541	D011899	2541
Ranitidine	Cimetidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
Ranitidine	Cimetidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
Ranitidine	Cimetidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
Ranitidine	Cimetidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
Ranitidine	Cimetidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
Ranitidine	Cimetidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
fluoxetine	risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
fluoxetine	risperidone	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
fluoxetine	risperidone	17	16	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
fluoxetine	risperidone	17	16	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	35636	none	35636
fluoxetine	risperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
fluoxetine	risperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
fluoxetine	risperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
fluoxetine	risperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
fluoxetine	risperidone	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
fluoxetine	risperidone	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
fluoxetine	risperidone	18	16	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
fluoxetine	risperidone	18	16	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
fluoxetine	risperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
fluoxetine	risperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	35636	none	35636
fluoxetine	risperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
fluoxetine	risperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	35636	none	35636
fluoxetine	risperidone	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
fluoxetine	risperidone	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
fluoxetine	risperidone	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
fluoxetine	risperidone	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
fluoxetine	risperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
fluoxetine	risperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
fluoxetine	risperidone	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
fluoxetine	risperidone	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
fluoxetine	risperidone	21	23	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
fluoxetine	risperidone	21	23	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	35636	none	35636
fluoxetine	risperidone	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
fluoxetine	risperidone	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
fluoxetine	risperidone	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
fluoxetine	risperidone	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
fluoxetine	risperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
fluoxetine	risperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
fluoxetine	risperidone	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
fluoxetine	risperidone	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	35636	none	35636
fluoxetine	risperidone	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
fluoxetine	risperidone	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	35636	none	35636
fluoxetine	risperidone	20	22	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
fluoxetine	risperidone	20	22	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	35636	none	35636
fluoxetine	carbamazepine	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
fluoxetine	Erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
fluoxetine	Erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
fluoxetine	Paroxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		none	none	none	none
fluoxetine	Paroxetine	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	none	none	none
fluoxetine	Paroxetine	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	none	none	none
fluoxetine	Paroxetine	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	none	none	none
fluoxetine	Paroxetine	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
fluoxetine	Paroxetine	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
fluoxetine	Paroxetine	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
fluoxetine	Paroxetine	21	20	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
fluoxetine	Paroxetine	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
fluoxetine	Paroxetine	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	none	none	none
fluoxetine	Paroxetine	20	20	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	none	none	none
fluoxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
fluoxetine	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
fluoxetine	erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
fluoxetine	erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
galantamine	risperidone	29	27	false	none	7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		none	35636	none	35636
galantamine	risperidone	29	27	false	none	7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		none	35636	none	35636
galantamine	risperidone	29	29	false	none	In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		none	35636	none	35636
galantamine	risperidone	29	29	false	none	In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		none	35636	none	35636
galantamine	risperidone	29	28	false	none	Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		none	35636	none	35636
galantamine	risperidone	29	28	false	none	Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		none	35636	none	35636
galantamine	donepezil	29	29	false	none	In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		none	none	none	none
risperidone	carbamazepine	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	carbamazepine	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	carbamazepine	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	carbamazepine	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	carbamazepine	23	25	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
risperidone	carbamazepine	23	25	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
risperidone	carbamazepine	23	24	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		35636	none	35636	none
risperidone	carbamazepine	23	24	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		35636	none	35636	none
risperidone	carbamazepine	22	23	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	carbamazepine	22	23	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	carbamazepine	22	24	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		35636	none	35636	none
risperidone	carbamazepine	22	24	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		35636	none	35636	none
risperidone	carbamazepine	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
risperidone	carbamazepine	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
risperidone	carbamazepine	25	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
risperidone	carbamazepine	25	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
risperidone	carbamazepine	25	24	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
risperidone	carbamazepine	25	24	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	none	35636	none
risperidone	carbamazepine	27	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	none	35636	none
risperidone	carbamazepine	27	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	none	35636	none
risperidone	carbamazepine	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
risperidone	carbamazepine	26	25	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
risperidone	carbamazepine	26	24	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
risperidone	carbamazepine	26	24	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
risperidone	Clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	Clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	Clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	Clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	Clozapine	7	7	false	none	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	Clozapine	7	7	false	none	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	Clozapine	8	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2626	35636	D003024
risperidone	Clozapine	8	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2626	35636	D003024
risperidone	Clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	2626	35636	D003024
risperidone	Clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	2626	35636	D003024
risperidone	rifampin	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
risperidone	rifampin	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
risperidone	rifampin	27	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	none	35636	none
risperidone	rifampin	27	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	none	35636	none
risperidone	rifampin	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
risperidone	rifampin	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	none	35636	none
risperidone	rifampin	28	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		35636	none	35636	none
risperidone	rifampin	28	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		35636	none	35636	none
risperidone	Erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	Erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	Erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	Erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	Erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	Erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	Erythromycin	22	22	false	none	Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	Erythromycin	22	22	false	none	Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	valproate	7	9	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
risperidone	valproate	7	9	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
risperidone	valproate	8	9	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
risperidone	valproate	8	9	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
risperidone	valproate	8	10	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
risperidone	valproate	8	10	true	negative	7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
risperidone	valproate	9	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
risperidone	valproate	9	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	40254	35636	40254
risperidone	valproate	9	10	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
risperidone	valproate	9	10	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
risperidone	valproate	10	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
risperidone	valproate	10	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
risperidone	valproate	10	10	true	positive	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
risperidone	valproate	10	10	true	positive	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  		35636	40254	35636	40254
risperidone	valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
risperidone	valproate	11	9	true	negative	7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
risperidone	valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
risperidone	valproate	11	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  		35636	40254	35636	40254
risperidone	valproate	12	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	40254	35636	40254
risperidone	valproate	12	10	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	40254	35636	40254
risperidone	Paroxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
risperidone	Paroxetine	17	17	true	positive	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
risperidone	Paroxetine	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
risperidone	Paroxetine	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
risperidone	Paroxetine	16	17	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
risperidone	Paroxetine	16	17	true	positive	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  		35636	none	35636	none
risperidone	Paroxetine	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
risperidone	Paroxetine	19	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
risperidone	Paroxetine	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
risperidone	Paroxetine	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
risperidone	Paroxetine	19	21	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
risperidone	Paroxetine	19	21	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
risperidone	Paroxetine	19	20	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
risperidone	Paroxetine	19	20	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
risperidone	Paroxetine	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
risperidone	Paroxetine	18	17	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	none	35636	none
risperidone	Paroxetine	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
risperidone	Paroxetine	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	none	35636	none
risperidone	Paroxetine	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
risperidone	Paroxetine	18	20	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
risperidone	Paroxetine	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
risperidone	Paroxetine	21	19	true	negative	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
risperidone	Paroxetine	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
risperidone	Paroxetine	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
risperidone	Paroxetine	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
risperidone	Paroxetine	21	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
risperidone	Paroxetine	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
risperidone	Paroxetine	20	19	true	positive	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
risperidone	Paroxetine	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
risperidone	Paroxetine	20	21	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	none	35636	none
risperidone	Paroxetine	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
risperidone	Paroxetine	20	20	true	positive	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	none	35636	none
risperidone	Paroxetine	23	21	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	Paroxetine	23	21	true	negative	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	Paroxetine	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	Paroxetine	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	Paroxetine	22	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	Paroxetine	22	20	true	negative	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
risperidone	ranitidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
risperidone	ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
risperidone	ranitidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
risperidone	ranitidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
risperidone	ranitidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
risperidone	ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
risperidone	ranitidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	9143	35636	D011899
risperidone	ranitidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
risperidone	ranitidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
risperidone	ranitidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
risperidone	ranitidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
risperidone	ranitidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
risperidone	ranitidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	9143	35636	D011899
risperidone	ranitidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
risperidone	ranitidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
risperidone	ranitidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
risperidone	ranitidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	9143	35636	D011899
risperidone	ranitidine	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	9143	35636	D011899
risperidone	ranitidine	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	9143	35636	D011899
risperidone	donepezil	27	29	false	none	7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
risperidone	donepezil	27	29	false	none	7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
risperidone	donepezil	29	29	false	none	In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
risperidone	donepezil	29	29	false	none	In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
risperidone	donepezil	28	29	false	none	Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
risperidone	donepezil	28	29	false	none	Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.  		35636	none	35636	none
risperidone	9-hydroxyrisperidone	2	4	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	2	4	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	3	4	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	4	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	11	12	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	11	13	false	none	7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	12	12	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	12	12	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	12	13	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	12	13	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	13	12	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	13	12	false	none	7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	13	13	false	none	Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	13	13	false	none	Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	16	18	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	16	18	true	negative	In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.  Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	19	21	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	19	21	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	18	19	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	18	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	22	23	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	22	23	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	27	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	27	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	28	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		35636	679314	35636	C079150
risperidone	9-hydroxyrisperidone	28	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  7.12 Drugs Metabolized by CYP 2D6    In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.  Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.  		35636	679314	35636	C079150
risperidone	Levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	Levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	Levodopa	2	3	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	Levodopa	2	3	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	Levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	Levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	Levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	6375	35636	D007980
risperidone	Levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	6375	35636	D007980
risperidone	Levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	6375	35636	D007980
risperidone	Levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	6375	35636	D007980
risperidone	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	clozapine	7	7	false	none	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	clozapine	7	7	false	none	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2626	35636	D003024
risperidone	clozapine	8	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2626	35636	D003024
risperidone	clozapine	8	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2626	35636	D003024
risperidone	clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	2626	35636	D003024
risperidone	clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		35636	2626	35636	D003024
risperidone	levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	levodopa	1	3	false	none	7 DRUG INTERACTIONS    7.1 Centrally-Acting Drugs and Alcohol    Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.  7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	levodopa	2	3	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	levodopa	2	3	false	none	7.2 Drugs with Hypotensive Effects    Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.  7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	levodopa	3	3	false	none	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  		35636	6375	35636	D007980
risperidone	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	6375	35636	D007980
risperidone	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		35636	6375	35636	D007980
risperidone	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	6375	35636	D007980
risperidone	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	6375	35636	D007980
risperidone	erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		35636	none	35636	none
risperidone	erythromycin	22	22	false	none	Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	erythromycin	22	22	false	none	Erythromycin:There were no significant interactions between risperidone and erythromycin.  		35636	none	35636	none
risperidone	Cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
risperidone	Cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
risperidone	Cimetidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
risperidone	Cimetidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
risperidone	Cimetidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
risperidone	Cimetidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
risperidone	Cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
risperidone	Cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		35636	2541	35636	2541
risperidone	Cimetidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
risperidone	Cimetidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
risperidone	Cimetidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
risperidone	Cimetidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
risperidone	Cimetidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
risperidone	Cimetidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		35636	2541	35636	2541
risperidone	Cimetidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2541	35636	2541
risperidone	Cimetidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2541	35636	2541
risperidone	Cimetidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2541	35636	2541
risperidone	Cimetidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		35636	2541	35636	2541
risperidone	Cimetidine	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2541	35636	2541
risperidone	Cimetidine	8	6	true	negative	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  		35636	2541	35636	2541
carbamazepine	rifampin	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
carbamazepine	rifampin	24	26	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	none	none	none
carbamazepine	Erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
carbamazepine	Erythromycin	24	22	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	none	none	none
carbamazepine	Paroxetine	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
carbamazepine	9-hydroxyrisperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
carbamazepine	9-hydroxyrisperidone	23	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
carbamazepine	9-hydroxyrisperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
carbamazepine	9-hydroxyrisperidone	23	23	true	positive	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
carbamazepine	9-hydroxyrisperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	679314	none	C079150
carbamazepine	9-hydroxyrisperidone	25	23	false	none	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  		none	679314	none	C079150
carbamazepine	9-hydroxyrisperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
carbamazepine	9-hydroxyrisperidone	25	26	false	none	The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
carbamazepine	9-hydroxyrisperidone	24	23	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	679314	none	C079150
carbamazepine	9-hydroxyrisperidone	24	23	true	negative	7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	679314	none	C079150
carbamazepine	9-hydroxyrisperidone	24	26	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
carbamazepine	9-hydroxyrisperidone	24	26	false	none	Plasma concentrations of carbamazepine did not appear to be affected.  The dose of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy.  Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
carbamazepine	erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	none	none	none
carbamazepine	erythromycin	24	22	true	negative	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  Plasma concentrations of carbamazepine did not appear to be affected.  		none	none	none	none
Clozapine	valproate	7	9	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		2626	40254	D003024	40254
Clozapine	valproate	7	9	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		2626	40254	D003024	40254
Clozapine	ranitidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	9143	D003024	D011899
Clozapine	ranitidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	9143	D003024	D011899
Clozapine	ranitidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	9143	D003024	D011899
Clozapine	ranitidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	9143	D003024	D011899
Clozapine	9-hydroxyrisperidone	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	679314	D003024	C079150
Clozapine	9-hydroxyrisperidone	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	679314	D003024	C079150
Clozapine	Cimetidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	2541	D003024	2541
Clozapine	Cimetidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	2541	D003024	2541
Clozapine	Cimetidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	2541	D003024	2541
Clozapine	Cimetidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	2541	D003024	2541
rifampin	9-hydroxyrisperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
rifampin	9-hydroxyrisperidone	26	26	false	none	Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment.  		none	679314	none	C079150
Erythromycin	Paroxetine	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
Erythromycin	Paroxetine	22	20	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
Erythromycin	9-hydroxyrisperidone	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	679314	none	C079150
Erythromycin	9-hydroxyrisperidone	22	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	679314	none	C079150
Erythromycin	9-hydroxyrisperidone	22	23	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
Erythromycin	9-hydroxyrisperidone	22	23	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
valproate	9-hydroxyrisperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		40254	679314	40254	C079150
valproate	9-hydroxyrisperidone	10	12	true	negative	However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.  7.9 Digoxin    Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.  7.10 Drugs That Inhibit CYP 2D6 and Other CYP Isozymes    Risperidone is metabolized to 9-hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs [see 12 CLINICAL PHARMACOLOGY].  		40254	679314	40254	C079150
valproate	clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	2626	40254	D003024
valproate	clozapine	9	7	true	negative	7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  7.7 Lithium    Repeated oral doses of risperidone (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) of lithium (N=13).  7.8 Valproate    Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (N=21).  		40254	2626	40254	D003024
Paroxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	17	19	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	17	18	true	negative	Fluoxetine and Paroxetine: Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily) have been shown to increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold, respectively.  Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	19	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	19	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	19	21	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	19	21	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	21	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	21	21	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	21	23	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	20	19	false	none	Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	20	18	true	negative	Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone.  Paroxetine lowered the concentration of 9-hydroxyrisperidone by about 10%.  When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Paroxetine	9-hydroxyrisperidone	20	21	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  		none	679314	none	C079150
Paroxetine	erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
Paroxetine	erythromycin	20	22	false	none	When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of risperidone.  The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		none	none	none	none
ranitidine	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	679314	D011899	C079150
ranitidine	9-hydroxyrisperidone	5	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	679314	D011899	C079150
ranitidine	9-hydroxyrisperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
ranitidine	9-hydroxyrisperidone	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
ranitidine	9-hydroxyrisperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
ranitidine	9-hydroxyrisperidone	6	4	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
ranitidine	9-hydroxyrisperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
ranitidine	9-hydroxyrisperidone	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	679314	D011899	C079150
ranitidine	Levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	6375	D011899	D007980
ranitidine	Levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	6375	D011899	D007980
ranitidine	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
ranitidine	clozapine	5	7	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
ranitidine	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
ranitidine	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		9143	2626	D011899	D003024
ranitidine	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	6375	D011899	D007980
ranitidine	levodopa	5	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	6375	D011899	D007980
ranitidine	Cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	2541	D011899	2541
ranitidine	Cimetidine	5	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		9143	2541	D011899	2541
ranitidine	Cimetidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
ranitidine	Cimetidine	5	6	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
ranitidine	Cimetidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
ranitidine	Cimetidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
ranitidine	Cimetidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
ranitidine	Cimetidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		9143	2541	D011899	2541
9-hydroxyrisperidone	Levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		679314	6375	C079150	D007980
9-hydroxyrisperidone	Levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		679314	6375	C079150	D007980
9-hydroxyrisperidone	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		679314	2626	C079150	D003024
9-hydroxyrisperidone	clozapine	6	7	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		679314	2626	C079150	D003024
9-hydroxyrisperidone	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		679314	6375	C079150	D007980
9-hydroxyrisperidone	levodopa	4	3	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  		679314	6375	C079150	D007980
9-hydroxyrisperidone	erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		679314	none	C079150	none
9-hydroxyrisperidone	erythromycin	21	22	false	none	The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied.  Erythromycin:There were no significant interactions between risperidone and erythromycin.  		679314	none	C079150	none
9-hydroxyrisperidone	erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		679314	none	C079150	none
9-hydroxyrisperidone	erythromycin	23	22	true	positive	Erythromycin:There were no significant interactions between risperidone and erythromycin.  7.11 Carbamazepine and Other Enzyme Inducers    Carbamazepine co-administration decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50%.  		679314	none	C079150	none
9-hydroxyrisperidone	Cimetidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		679314	2541	C079150	2541
9-hydroxyrisperidone	Cimetidine	4	5	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		679314	2541	C079150	2541
9-hydroxyrisperidone	Cimetidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		679314	2541	C079150	2541
9-hydroxyrisperidone	Cimetidine	4	6	true	negative	7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		679314	2541	C079150	2541
9-hydroxyrisperidone	Cimetidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		679314	2541	C079150	2541
9-hydroxyrisperidone	Cimetidine	6	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		679314	2541	C079150	2541
9-hydroxyrisperidone	Cimetidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		679314	2541	C079150	2541
9-hydroxyrisperidone	Cimetidine	6	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  		679314	2541	C079150	2541
Levodopa	Cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		6375	2541	D007980	2541
Levodopa	Cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		6375	2541	D007980	2541
clozapine	Cimetidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	2541	D003024	2541
clozapine	Cimetidine	7	5	true	positive	7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	2541	D003024	2541
clozapine	Cimetidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	2541	D003024	2541
clozapine	Cimetidine	7	6	true	positive	However, cimetidine did not affect the AUC of risperidone and 9-hydroxyrisperidone combined, whereas ranitidine increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20%.  7.6 Clozapine    Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.  		2626	2541	D003024	2541
levodopa	Cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		6375	2541	D007980	2541
levodopa	Cimetidine	3	5	true	negative	7.3 Levodopa and Dopamine Agonists    Risperidone may antagonize the effects of levodopa and dopamine agonists.  7.4 Amitriptyline    Amitriptyline did not affect the pharmacokinetics of risperidone or risperidone and 9-hydroxyrisperidone combined.  7.5 Cimetidine and Ranitidine    Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively.  		6375	2541	D007980	2541
